Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Two Week Cycle

Sponsor ID

PX-171-001

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

N/A

Product

N/A

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.